See below for our upcoming events. If you have any queries, please don’t hesitate to contact us.
EIS: The Basics - The Modern World Of EIS (Episode 1)
3rd October 2023
Agenda: A look at the tax reliefs and the history of EIS. What is the Government’s objective of the Scheme and what should advisers bear in mind? At…
Event Details
EIS: The Basics - Trigger Points (Episode 2)
10th October 2023
Agenda: A look at the tax reliefs and the history of EIS. What is the Government’s objective of the Scheme and what should advisers bear in mind? At…
Event Details
EIS: The Basics - Due Diligence & Research (Episode 3)
17th October 2023
Agenda: A look at the tax reliefs and the history of EIS. What is the Government’s objective of the Scheme and what should advisers bear in mind? At…
Event Details
Business Relief: The Basics - An introduction to Business Relief as a primary IHT planning tool (Episode 1)
31st October 2023
Agenda: In this session, we will discuss what Business Relief is, how it integrates with IHT and how it operates in comparison to other more…
Event Details
Business Relief: The Basics - How Business Relief propositions work – using practical examples (Episode 2)
7th November 2023
Agenda: We will investigate which clients are most suitable for Business Relief and where the trigger points are. This includes an interesting look…
Event Details
Business Relief: The Basics - Due diligence considerations to take into account when comparing Business Relief propositions (Episode 3)
14th November 2023
Agenda: Understanding the different types of risks, considering how to select a fund manager and identifying what third party support is available to…
Event Details
Business Relief: The Basics - An in-depth look into renewable energy as an asset class (Episode 4)
21st November 2023
Agenda: An interesting look into the hotly topical renewable energy sector; looking into the power of sustainable investing and why we invest in this…
Event Details
EIS: Advanced - Journey of an Investee Company - Episode 1
28th November 2023
Agenda: Investigating the journey of an early-stage company as they grow to the point of exit, with examples provided on the potential returns’…
Event Details
EIS: Advanced - More than just a tax tool - Episode 2
5th December 2023
Agenda: Investigating the journey of an early-stage company as they grow to the point of exit, with examples provided on the potential returns’…
Event Details
EIS: Advanced - Financial Planning Considerations - Episode 3
12th December 2023
Agenda: Investigating the journey of an early-stage company as they grow to the point of exit, with examples provided on the potential returns’…
Event DetailsOur Products
An opportunity to participate in a range of diverse portfolios, proactively managed by our sector experienced team. Tax advantages are potentially available via the Enterprise Investment Scheme and Seed Enterprise Investment Scheme. Please view our specific product pages for more information. Financial Advice is recommended.
An opportunity for investors participate in a portfolio of growth-focused technology companies, whilst taking advantage of the potential tax benefits available under the Enterprise Investment Scheme.
An opportunity for investors to participate in a portfolio of growth-focused healthcare innovation companies, whilst taking advantage of the potential tax benefits available under the Enterprise Investment Scheme.
An asset-backed opportunity for investors to target long-term capital growth by investing in renewable energy generating trading assets.
An opportunity for investors to participate in a portfolio of seed-stage healthcare innovation companies, whilst taking advantage of the potential tax benefits available under the Seed Enterprise Investment Scheme.
An opportunity for investors to participate in a portfolio of seed-stage technology innovation companies, whilst taking advantage of the potential tax benefits available under the Seed Enterprise Investment Scheme.
The Private Investor Network of Deepbridge Capital, enabling experienced investors to define their own portfolio of innovative Life Sciences and Technology companies.
